Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Bryostatin-1: Phase IIa ongoing

    Neurotrope Inc. (OTCQB:NTRP), Newark, N.J. Product: Bryostatin-1 Business: Neurology Molecular target: Protein kinase C (PKC) epsilon (PKCE) Description: Protein kinase C (PKC) epsilon (PKCE) activator Indication: Treat…

    Published on 12/8/2014
  • Bucillamine: Phase IIa start

    Revive Therapeutics Ltd. (TSX-V:RVV), Vaughan, Ontario Product: Bucillamine (REV-002) Business: Endocrine/Metabolic Molecular target: NA Description: Combination of allopurinol and bucillamine, a cysteine-derived thiol …

    Published on 12/8/2014
  • Cx601: Completed Phase III enrollment

    TiGenix N.V. (Euronext:TIG), Leuven, Belgium Product: Cx601 Business: Autoimmune Molecular target: NA Description: Allogeneic expanded adipose derived stem cells Indication: Treat complex perianal fistulas in Crohns …

    Published on 12/8/2014
  • DEZ-001: Completed Phase I enrollment

    Dezima Pharma Beta.V., Naarden, the Netherlands Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: DEZ-001, TA-8995 Business: Endocrine/Metabolic Molecular target: Cholesteryl ester transfer protein (…

    Published on 12/8/2014
  • Eteplirsen: Phase II started

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: Eteplirsen (AVI-4658) Business: Musculoskeletal Molecular target: DNA Description: Phosphorodiamidate morpholino oligomer (PMO) targeting exon 51 …

    Published on 12/8/2014
  • Eteplirsen: Phase III started

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: Eteplirsen (AVI-4658) Business: Musculoskeletal Molecular target: DNA Description: Phosphorodiamidate morpholino oligomer (PMO) targeting exon 51 …

    Published on 12/8/2014
  • Filgotinib: Completed Phase IIb enrollment

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Filgotinib (GLPG0634) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) Description: Janus kinase…

    Published on 12/8/2014
  • FX006: Phase IIb resumed

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Autoimmune Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide Indication: Treat…

    Published on 12/8/2014
  • GKT137831: Completed Phase II enrollment

    Genkyotex S.A., Plan-les-Ouates, Switzerland Product: GKT137831 Business: Renal Molecular target: NADPH oxidase 1 (NOX1); NADPH oxidase 4 (NOX4) Description: Dual NADPH oxidase 1 (NOX1) and NOX4 inhibitor Indication: …

    Published on 12/8/2014
  • Heplisav: Phase III ongoing

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: Heplisav (V270) Business: Infectious Molecular target: Toll-like receptor 9 (TLR9) Description: Hepatitis Beta surface antigen (HBsAg) given with …

    Published on 12/8/2014
  • Irinotecan: Phase I started

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. PharmaEngine Inc. (GreTai:4162), Taipei, Taiwan Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Irinotecan (nal-IRI) (PEP02, MM-398) Business…

    Published on 12/8/2014
  • Livatag doxorubicin: Phase III ongoing

    Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Livatag doxorubicin (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin Indication: Treat hepatocellular …

    Published on 12/8/2014
  • Lodonal: Clinical trial started

    TNI BioTech Inc. (OTCQB:TNIB), Bethesda, Md. Product: Lodonal (IRT-103 LDN) Business: Infectious Molecular target: Opioid receptor (OPR) Description: Active immunotherapy with low-dose naltrexone (LDN) that activates …

    Published on 12/8/2014
  • MAT9001: Clinical trial started

    Matinas BioPharma Holdings Inc. (OTCQB:MTNB), Bedminster, N.J. Product: MAT9001 Business: Endocrine/Metabolic Molecular target: NA Description: Next-generation omega-3 fatty acids, including docosapentaenoic acid (DPA) …

    Published on 12/8/2014
  • OTO-104: Completed Phase IIb enrollment

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: OTO-104 Business: Other Molecular target: NA Description: Sustained-release dexamethasone gel delivered via intratympanic injection Indication: Treat Menieres …

    Published on 12/8/2014
  • Probuphine buprenorphine: Completed Phase III enrollment

    Titan Pharmaceuticals Inc. (OTCBB:TTNP), South San Francisco, Calif. Product: Probuphine buprenorphine Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Subcutaneous rod implant for …

    Published on 12/8/2014
  • Quadrivalent seasonal influenza VLP vaccine: Phase II started

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: Quadrivalent seasonal influenza VLP vaccine Business: Infectious Molecular target: NA Description: Quadrivalent virus-like particle (VLP) vaccine containing 2 …

    Published on 12/8/2014
  • Rilotumumab: Phase III discontinued

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Rilotumumab (AMG 102) Business: Cancer Molecular target: Hepatocyte growth factor/scatter factor (HGF/SF) Description: Human mAb against human hepatocyte growth …

    Published on 12/8/2014
  • Rociletinib: Phase II/III started

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Product: Rociletinib (AVL-301) (formerly CO-1686) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) …

    Published on 12/8/2014
  • RSV F vaccine: Phase I started

    Novavax Inc. (NASDAQ:NVAX), Gaithersburg, Md. Product: RSV F vaccine Business: Infectious Molecular target: NA Description: Respiratory syncytial virus (RSV) vaccine directed against the viral fusion F protein and …

    Published on 12/8/2014
  • SYN-004: Phase Ia started

    Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-004 (formerly P3A) Business: Infectious Molecular target: NA Description: Second-generation, oral beta lactamase (LACTB) that binds with and neutralizes…

    Published on 12/8/2014
  • TargomiRs: Phase I started

    EnGeneIC Ltd., Lane Cove West, Australia Product: TargomiRs Business: Cancer Molecular target: NA Description: EGFR-targeting, EnGeneIC delivery vehicle (EDV) nanocells packaged with miR-16 microRNAs Indication: Treat …

    Published on 12/8/2014
  • Viaskin Milk: Phase I/II started

    DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT), Bagneux, France Product: Viaskin Milk Business: Inflammation Molecular target: NA Description: Milk proteins epicutaneously delivered by Viaskin patch technology …

    Published on 12/8/2014
  • VPI-2690B: Phase II started

    Vascular Pharmaceuticals Inc., Chapel Hill, N.C. Product: VPI-2690B Business: Renal Molecular target: Integrin alpha(5)beta(3) (CD49e/CD61) Description: Humanized mAb against integrin alpha(5)beta (3) (CD49e/CD61) …

    Published on 12/8/2014
  • ZP4207: Phase I started

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Product: ZP4207 Business: Endocrine/Metabolic Molecular target: NA Description: Stable glucagon analog in a liquid dosage form as a ready-to-use rescue pen Indication: …

    Published on 12/8/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993